CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin
when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab
before donor stem cell transplant in treating patients with lymphoid malignancies. Giving
chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a
donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal
cell and helps stop the patient's immune system from rejecting the donor's stem cells.
Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. When the healthy stem cells from a donor are infused into the
patient they may help the patient's bone marrow make stem cells, red blood cells, white blood
cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system
response against the body's normal cells. Giving fludarabine phosphate and bendamustine
hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may
stop this from happening.